These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 19802994

  • 1. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
    Acred P, Ryan DM, Sowa MA, Watts CM.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
    [Abstract] [Full Text] [Related]

  • 2. In-vitro comparison of ceftazidime and nine other antimicrobial agents against hospital strains of Gram-negative bacteria.
    Wilkinson LD, Gentry LO.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():53-6. PubMed ID: 19802969
    [Abstract] [Full Text] [Related]

  • 3. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
    Giamarellou H.
    Am J Med; 1986 Jun 30; 80(6B):126-37. PubMed ID: 3088998
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T, Otsuki M, Hatano K, Nishihara Y.
    Chemotherapy; 1994 Jun 30; 40(3):167-82. PubMed ID: 8205935
    [Abstract] [Full Text] [Related]

  • 5. In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin.
    Neu HC.
    J Antimicrob Chemother; 1981 Sep 30; 8 Suppl B():131-4. PubMed ID: 19810175
    [Abstract] [Full Text] [Related]

  • 6. Susceptibility of gentamicin sensitive and resistant gram negative bacilli to ceftazidime.
    Bremner DA.
    Pathology; 1987 Jul 30; 19(3):274-6. PubMed ID: 3124067
    [Abstract] [Full Text] [Related]

  • 7. In-vitro studies with ceftazidime against aerobic gram-negative bacilli and Bacteroides fragilis group.
    Acuna G, Johnston J, Young LS, Martin WJ.
    J Antimicrob Chemother; 1981 Sep 30; 8 Suppl B():83-9. PubMed ID: 19810170
    [Abstract] [Full Text] [Related]

  • 8. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN, Barry AL, Thornsberry C, Gerlach EH, Fuchs PC, Gavan TL, Sommers HM.
    J Antimicrob Chemother; 1981 Sep 30; 8 Suppl B():187-211. PubMed ID: 19802985
    [Abstract] [Full Text] [Related]

  • 9. Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
    Prince AS, Neu HC.
    Antimicrob Agents Chemother; 1981 Oct 30; 20(4):545-6. PubMed ID: 6282199
    [Abstract] [Full Text] [Related]

  • 10. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B.
    J Antimicrob Chemother; 1981 Sep 30; 8 Suppl B():97-105. PubMed ID: 19810171
    [Abstract] [Full Text] [Related]

  • 11. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
    Braveny I, Machka K, Elsser R.
    Infection; 1982 Jan 30; 10(1):45-9. PubMed ID: 6279523
    [Abstract] [Full Text] [Related]

  • 12. [In vitro activity of cefmenoxime (SCE 1365) against 616 hospital strains of gram-negative bacilli chosen for beta-lactam resistance. Comparison with cefotaxime, lamoxactam and ceftazidime].
    Le Noc P, Bryskier A, Le Noc D.
    Pathol Biol (Paris); 1983 May 30; 31(5):351-6. PubMed ID: 6312396
    [Abstract] [Full Text] [Related]

  • 13. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan 30; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of antimicrobial susceptibility for beta-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006).
    Ishii Y, Tateda K, Yamaguchi K, Japan Antimicrobial Resistance Surveillance Participants Group (JARS).
    Diagn Microbiol Infect Dis; 2008 Feb 30; 60(2):177-83. PubMed ID: 17931820
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
    Perrymann F, Flournoy DJ, Qadri SM.
    Chemotherapy; 1983 Feb 30; 29(1):37-42. PubMed ID: 6219865
    [Abstract] [Full Text] [Related]

  • 16. The in-vitro activity of ceftazidime against clinically important pathogens.
    Knothe H, Dette GA.
    J Antimicrob Chemother; 1981 Sep 30; 8 Suppl B():33-41. PubMed ID: 19810167
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S, Hiraoka M, Inoue M, Tomatsu K, Hirano M, Mitsuhashi S.
    Drugs Exp Clin Res; 1989 Sep 30; 15(1):1-10. PubMed ID: 2663406
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.